Merck And Teva Settle Temodar Patent Suit, But Appeals Case Continues
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva will launch its generic only if an appeals court finds the Temodar patent is unenforceable; otherwise it can do so six months before the patent expires.